Curis, Inc. announced a net loss of $24.2 million for Q1 2026, reflecting ongoing investment in its drug candidate emavusertib, which is being tested in lymphoma and chronic lymphocytic leukemia (CLL) trials. The company is progressing clinical studies combining emavusertib with BTK inhibitors, aiming for accelerated approval in primary CNS lymphoma and promising deeper responses in CLL. Curis secured $80.8 million in financing earlier this year and expects key trial data updates by late 2026 and early 2027, supporting its development and regulatory goals. Cash on hand and potential warrant exercises are expected to fund operations into the second half of 2027.
Zcash (ZEC) is approaching the $600 mark after breaking out of a multi-week consolidation, showing strong bullish momentum. The price has surpassed key moving averages and resistance levels, supported by healthy trading volume and positive technical ...
Ethereum is gaining strength, trading near $1,920 after surpassing its 26-day and 50-day EMAs, signaling renewed buying interest. The next key resistance is the 100-day EMA at around $1,944; a daily close above this could lead Ethereum toward the 200...
Bitcoin (BTC) is showing signs of recovery after a prolonged downtrend, breaking above its 26-day and 50-day exponential moving averages (EMAs) near $63,400 and $64,100 respectively. This technical rebound suggests strengthening short-term momentum a...
Fundstrat's Granny Shot US-Small & Mid-Cap ETF (GRNJ) has delivered strong year-to-date returns, beating similar ETFs like VOT and VOO despite its higher 0.75% expense ratio. The fund targets stocks at the intersection of major secular trends, partic...
ETHSystems, a new Ethereum-focused non-profit backed by Bitmine Immersion Technologies and Ethereum co-founder Joe Lubin, aims to enhance privacy on the Ethereum network for institutional use. This marks the third non-profit stepping in as the Ethere...
